Germany expands access to colorectal cancer screening with updated guidelines.
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostics firm specializing in early cancer detection, announces the launch of an enhanced ColoAlert colorectal cancer (CRC) screening test by its partner, GANZIMMUN Diagnostics. Available nationwide in Germany since January, the test is launched in time for March’s Colorectal Cancer Awareness Month.
Initially introduced in mid-2024, the improved ColoAlert incorporates cutting-edge technology, including a proprietary DNA stabilizing buffer, ensuring accurate results despite varying sample sizes.
This collaboration highlights both companies’ commitment to colorectal cancer prevention through innovation and accessibility. Mainz Biomed’s VP of Commercial Operations, Tarrin Khairi-Taraki, stated, “This achievement advances our mission to improve colorectal cancer prevention and detection. We’re pleased to support GANZIMMUN in making this groundbreaking test available to patients during this crucial awareness period.”
Enhanced Awareness and Accessibility via Harmonized Screening Guidelines
The launch coincides with March’s Colorectal Cancer Awareness Month, a global initiative promoting early detection of this preventable cancer. This strategic timing underscores the life-saving potential of innovative diagnostics like ColoAlert.
Moreover, the enhanced ColoAlert’s launch coincides with increased colorectal cancer screening awareness in Germany. Germany recently updated its national screening program to provide equal access for men and women aged 50 and older, rectifying previous gender-based disparities in risk assessment. Research from the Institute for Quality and Efficiency in Health Care (IQWiG) revealed no significant gender differences in recommended screening methods or intervals, enabling uniform practices. These updated guidelines, by streamlining screening and promoting equal access, are expected to increase participation and enhance preventative healthcare integration.
The joint launch exemplifies Mainz Biomed and GANZIMMUN’s shared dedication to advancing colorectal cancer diagnostics through state-of-the-art innovation. This advancement enables laboratory partners to offer a superior screening solution that aligns seamlessly with current healthcare needs and trends during a pivotal moment in the fight against CRC.
.
Please follow us to stay up to date:
About GANZIMMUN Diagnostics
GANZIMMUN Diagnostics is a leading European laboratory specializing in preventive and complementary medicine. Led by Dr. med. Patrik Zickgraf, its 420+ employees process around 5,500 lab orders daily. Their extensive diagnostic services encompass over 4,000 lab parameters, including innovative tests such as ColoAlert.
To learn more, visit
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening diseases. Its flagship product is ColoAlert®, an accurate, non-invasive, and user-friendly early detection diagnostic test for colorectal cancer. ColoAlert® is sold in Europe and the UAE. The Company is conducting a pivotal FDA clinical trial for US regulatory approval. Mainz Biomed’s pipeline also includes PancAlert, an early-stage pancreatic cancer screening test using real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit or follow us on , and .
For media inquiries
MC Services AG
Anne Hennecke / Simone Neeten
+49 211 529252 20
For investor inquiries, please contact
Forward-Looking Statements
This press release contains forward-looking statements, subject to risks and uncertainties. Actual results may differ materially. Factors that could cause such differences include: (i) failure to meet development targets; (ii) changes in laws or regulations; (iii) the impact of the COVID-19 pandemic; and (iv) other risks discussed in the Company’s SEC filings, available at www.sec.gov. Any forward-looking statement speaks only as of its date, and Mainz Biomed has no obligation to update it.
